Celldex Therapeutics reported $724.93M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Agenus USD 78.81M 16.47M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Celldex Therapeutics USD 724.93M 265.71M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Northwest Biotherapeutics USD 6.2M 996K Mar/2026
Pfizer USD 41.36B 1.46B Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026